6WX4 image
Deposition Date 2020-05-09
Release Date 2020-05-20
Last Version Date 2023-11-15
Entry Detail
PDB ID:
6WX4
Title:
Crystal structure of the SARS CoV-2 Papain-like protease in complex with peptide inhibitor VIR251
Biological Source:
Method Details:
Experimental Method:
Resolution:
1.66 Å
R-Value Free:
0.19
R-Value Work:
0.16
R-Value Observed:
0.17
Space Group:
I 2 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Non-structural protein 3
Gene (Uniprot):rep
Chain IDs:A (auth: D)
Chain Length:326
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2
Polymer Type:polypeptide(L)
Molecule:VIR251
Chain IDs:B (auth: I)
Chain Length:5
Number of Molecules:1
Biological Source:synthetic construct
Ligand Molecules
Peptide-like Molecules
PRD_002390
Primary Citation
Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design.
Sci Adv 6 ? ? (2020)
PMID: 33067239 DOI: 10.1126/sciadv.abd4596

Abstact

Viral papain-like cysteine protease (PLpro, NSP3) is essential for SARS-CoV-2 replication and represents a promising target for the development of antiviral drugs. Here, we used a combinatorial substrate library and performed comprehensive activity profiling of SARS-CoV-2 PLpro. On the scaffold of the best hits from positional scanning, we designed optimal fluorogenic substrates and irreversible inhibitors with a high degree of selectivity for SARS PLpro. We determined crystal structures of two of these inhibitors in complex with SARS-CoV-2 PLpro that reveals their inhibitory mechanisms and provides a molecular basis for the observed substrate specificity profiles. Last, we demonstrate that SARS-CoV-2 PLpro harbors deISGylating activity similar to SARSCoV-1 PLpro but its ability to hydrolyze K48-linked Ub chains is diminished, which our sequence and structure analysis provides a basis for. Together, this work has revealed the molecular rules governing PLpro substrate specificity and provides a framework for development of inhibitors with potential therapeutic value or drug repurposing.

Legend

Protein

Chemical

Disease

Primary Citation of related structures